Categories

Subscribe!

Screen-Shot-2026-07-18-at-1.31.53-PM

Not All Stem Cells Created Equal: What Physicians Should Ask Before Trusting Regenerative Products – Kevin Kearns

By Coach Kevin Kearns, Exercise Physiologist | Former UFC Strength & Conditioning Coach | Founder, Burn WithKearns & BWK Authentic Edge

The regenerative medicine industry is growing rapidly. Stem cells, extracellular vesicles commonly called exosomes, and other cellular technologies are attracting attention from physicians, researchers, longevity specialists, and patients.

But amid the excitement, one fundamental question is often overlooked:

Where does the biological material actually come from?

That question recently surfaced during a conversation with a regenerative medicine educator. It led to a much deeper discussion about tissue origins, donor screening, laboratory characterization, and the difference between scientific documentation and marketing.

After more than three decades working in human performance, I’ve learned that the most important questions are often the simplest.

In regenerative medicine, the source matters. But the source alone never tells the whole story.

Wharton’s Jelly, Placenta, and Cord Blood: Understanding the Differences

These terms are sometimes used interchangeably, but they describe different biological materials.

Wharton’s jelly is the gelatinous connective tissue surrounding the blood vessels within the umbilical cord. It is one recognized source of mesenchymal stromal cells, commonly referred to as MSCs.

Placental tissue contains several distinct anatomical compartments, including the amnion and chorion. Different compartments may yield different cell populations.

Umbilical cord blood is primarily known as a source of hematopoietic stem cells, which differ from MSCs.

When a manufacturer describes a product as “umbilical cord-derived” or “placenta-derived,” physicians should ask for greater specificity.

Which tissue compartment was used? How were the cells isolated? How was their identity established?

Those are reasonable scientific questions—not unnecessary obstacles.

What About Muse Cells?

Muse cells, or multilineage-differentiating stress-enduring cells, are a population studied for their distinctive biological characteristics, including expression of the SSEA-3 marker.

Their identification requires appropriate characterization.

A Certificate of Analysis may report markers such as SSEA-3, CD90, and CD105, along with cell count and viability.

Those measurements can provide useful information about a particular batch. However, they do not independently establish the original tissue source, clinical effectiveness, or suitability for patient administration.

Physicians should understand the difference between identifying a cell population and demonstrating that a finished cellular product is safe and effective for a particular medical application.

Exosomes are a subset of extracellular vesicles released by cells. Their characteristics can vary depending on the producing cells, culture conditions, isolation methods, purification processes, and storage.

A preparation described as placental MSC-derived is not automatically superior or inferior to one derived from another source.

A meaningful evaluation should examine the parent-cell population, extracellular-vesicle characterization, purity, biological activity, manufacturing consistency, and supporting safety evidence.

Dismissing a product solely because of its tissue origin is no substitute for evaluating its actual characteristics.

Equally, a promising tissue source is not proof of clinical benefit.

What Do We Know About the Donors?

Another important question concerns the women who donate birth-associated tissues.

Donor privacy must be protected. Physicians generally do not need access to names, addresses, or identifying personal information.

But appropriate, de-identified information about donor eligibility and screening can be essential.

This may include relevant maternal health history, infectious-disease screening, informed consent, tissue procurement procedures, and traceability from collection through manufacturing.

Questions about donor ancestry or ethnicity should be approached scientifically rather than through assumptions. Race alone cannot establish product quality, safety, or immune compatibility.

For living donor-derived cells, immunogenicity and other product-specific biological characteristics may be important.

The appropriate question is not simply who donated the tissue. It is whether the donor material and finished product have been evaluated through a documented, scientifically appropriate process.

A Certificate of Analysis Is Important—but It Is Not the Whole Story

A COA can provide valuable batch-specific information.

Depending on the product, testing may address cell identity, viability, sterility, endotoxins, purity, and other quality attributes.

But a COA is not a substitute for a complete manufacturing history, clinical evidence, or regulatory authorization.

Physicians should also understand how the manufacturer establishes traceability, validates relevant processes, and determines whether a product meets its release specifications.

Transparency and Intellectual Property Can Coexist

Regenerative biotechnology companies may invest years developing proprietary isolation techniques, cell-selection methods, manufacturing procedures, and research programs.

Protecting that intellectual property is legitimate.

However, protecting proprietary methods should not mean withholding information necessary for responsible clinical evaluation.

A practical approach is to provide verified product descriptions, appropriate quality documentation, and regulatory information during initial due diligence.

More detailed confidential manufacturing information can be reviewed under a properly structured nondisclosure agreement when appropriate.

The objective should be to protect innovation while supporting meaningful scientific scrutiny.

Experience Matters. Evidence Matters More.

A company with 20 years of experience may have valuable manufacturing knowledge, institutional expertise, and research history.

But experience alone does not establish the safety, effectiveness, or regulatory status of an individual product.

The same applies to newer companies entering the field.

What matters is whether their claims can be supported by reliable documentation, appropriate testing, and evidence relevant to the intended application.

In the United States, many marketed stem-cell and exosome products are not FDA-approved for the uses being promoted. Physicians must independently evaluate the regulatory status of any specific product.

Education Before Application

The future of regenerative medicine will not be determined by the loudest marketing claims.

It will depend on scientific rigor, responsible manufacturing, transparent documentation, appropriate clinical research, and informed medical decision-making.

Whether you’re a physician, researcher, healthcare entrepreneur, or someone exploring longevity science, start with the fundamental questions:

Where did it come from? What exactly is it? How was it tested? What evidence supports its use?

And is its intended clinical use legally authorized?

Know the source. Understand the science. Demand the documentation.

That’s how regenerative medicine earns credibility.

___

Coach Kevin Kearns is an exercise physiologist, former UFC strength and conditioning coach, and founder of Burn With Kearns and BWK Authentic Edge. His work focuses on human performance, longevity education, and emerging regenerative technologies.

This article is educational and does not constitute medical advice or an endorsement of unapproved cellular therapies.

www.BWKAuthenticEdge.com

Posted in ,

Leave a Comment